fulvestrant has been researched along with Bone Loss, Osteoclastic in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (20.00) | 18.2507 |
| 2000's | 7 (70.00) | 29.6817 |
| 2010's | 1 (10.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Agrawal, A; Cheung, KL; Eastell, R; Hannon, RA; Robertson, JF | 1 |
| Fong, C; Yang, M; Yao, X; Zhang, D; Zhang, J | 1 |
| Audebert, A; Donnez, J; Hervais Vivancos, B; Jadoul, P; Kudela, M | 1 |
| Härkönen, PL; Hentunen, TA; Michael, H; Väänänen, HK | 1 |
| Gorny, G; Maran, A; Oursler, MJ; Shogren, KL; Turner, RT; Yaszemski, MJ; Zhang, M | 1 |
| Gyokusen, M; Kaneko, S; Kondo, R; Sato, I; Sato, J; Sato, M; Shimizu, K; Tsutsui, M; Yamanaka, M | 1 |
| Härkönen, PL; Hentunen, TA; Kangas, L; Michael, H; Väänänen, HK | 1 |
| Denger, S; Gannon, F; Reid, G | 1 |
| Chambers, TJ; Gallagher, A; Tobias, JH | 1 |
| Blair, HC; Jordan, SE; McDonald, JM; McKenna, MA; Williams, JP | 1 |
2 trial(s) available for fulvestrant and Bone Loss, Osteoclastic
| Article | Year |
|---|---|
Bone turnover markers in postmenopausal breast cancer treated with fulvestrant--a pilot study.
Topics: Aged; Alkaline Phosphatase; Antineoplastic Agents; Biomarkers; Bone Density; Bone Remodeling; Bone Resorption; Breast Neoplasms; Collagen Type I; Estradiol; Female; Fulvestrant; Humans; Middle Aged; Peptides; Pilot Projects; Postmenopause; Treatment Outcome | 2009 |
A randomized, placebo-controlled, dose-ranging trial comparing fulvestrant with goserelin in premenopausal patients with uterine fibroids awaiting hysterectomy.
Topics: Adult; Biopsy; Bone Resorption; Endometrium; Estradiol; Estrogen Antagonists; Estrogen Receptor Modulators; Female; Fulvestrant; Goserelin; Humans; Hysterectomy; Leiomyoma; Middle Aged; Premenopause; Receptors, Estrogen; Receptors, Progesterone; Uterine Neoplasms | 2003 |
8 other study(ies) available for fulvestrant and Bone Loss, Osteoclastic
| Article | Year |
|---|---|
Herba epimedii flavonoids suppress osteoclastic differentiation and bone resorption by inducing G2/M arrest and apoptosis.
Topics: Acid Phosphatase; Animals; Animals, Newborn; Apoptosis; Bone Resorption; Cell Cycle Checkpoints; Cell Differentiation; Cell Division; Cell Line; Cell Proliferation; Drugs, Chinese Herbal; Epimedium; Estradiol; Flavonoids; Fulvestrant; G2 Phase; Inhibitory Concentration 50; Isoenzymes; Matrix Metalloproteinase 9; Molecular Structure; Monocytes; Osteoclasts; Rabbits; RANK Ligand; Reverse Transcriptase Polymerase Chain Reaction; Tartrate-Resistant Acid Phosphatase | 2012 |
Estrogen and testosterone use different cellular pathways to inhibit osteoclastogenesis and bone resorption.
Topics: Acid Phosphatase; Adult; Androgen Antagonists; Animals; Bone Resorption; Carrier Proteins; Cattle; Cell Differentiation; Cell Line, Tumor; Coculture Techniques; Dexamethasone; Dose-Response Relationship, Drug; Estradiol; Estrogen Antagonists; Estrogens; Flutamide; Fulvestrant; Glycoproteins; Humans; Isoenzymes; Lipopolysaccharide Receptors; Macrophage Colony-Stimulating Factor; Male; Membrane Glycoproteins; Monocytes; Osteoclasts; Osteoprotegerin; RANK Ligand; Receptor Activator of Nuclear Factor-kappa B; Receptors, Cytoplasmic and Nuclear; Receptors, Tumor Necrosis Factor; Tartrate-Resistant Acid Phosphatase; Testosterone; Tumor Necrosis Factor-alpha | 2005 |
2-methoxyestradiol inhibits differentiation and is cytotoxic to osteoclasts.
Topics: 2-Methoxyestradiol; Animals; Apoptosis; Bone Resorption; Cell Differentiation; Cell Line; Cell Survival; Cells, Cultured; Cytokines; Estradiol; Estrogen Receptor Modulators; Female; Fulvestrant; Lymphotoxin-alpha; Lymphotoxin-beta; Membrane Proteins; Mice; Osteoclasts; Rats; RNA, Messenger | 2006 |
Estrogen-like activity and prevention effect of bone loss in calcium deficient ovariectomized rats by the extract of Pleurotus eryngii.
Topics: Animals; Bone Density; Bone Resorption; Calcium; Cell Line, Tumor; Cell Proliferation; Estradiol; Estrogen Antagonists; Estrogens, Non-Steroidal; Female; Fulvestrant; Humans; Osteoporosis; Ovariectomy; Plant Extracts; Pleurotus; Rats; Rats, Sprague-Dawley | 2006 |
Differential effects of selective oestrogen receptor modulators (SERMs) tamoxifen, ospemifene and raloxifene on human osteoclasts in vitro.
Topics: Animals; Apoptosis; Bone Resorption; Cattle; Cell Differentiation; Cell Line, Tumor; Cells, Cultured; Coculture Techniques; Dexamethasone; Dose-Response Relationship, Drug; Estradiol; Estrogen Antagonists; Fulvestrant; Humans; Lipopolysaccharide Receptors; Macrophage Colony-Stimulating Factor; Monocytes; Osteoclasts; Osteoprotegerin; Raloxifene Hydrochloride; RANK Ligand; Selective Estrogen Receptor Modulators; Tamoxifen; Time Factors; Tumor Necrosis Factor-alpha | 2007 |
Expression of the estrogen receptor during differentiation of human osteoclasts.
Topics: Bone Resorption; Cell Differentiation; Cells, Cultured; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Estrogen Receptor beta; Fulvestrant; Gene Expression Profiling; Humans; Microscopy, Electron, Scanning; Monocytes; Osteoclasts; Promoter Regions, Genetic; Signal Transduction; Trefoil Factor-1; Tumor Suppressor Proteins | 2008 |
The estrogen antagonist ICI 182,780 reduces cancellous bone volume in female rats.
Topics: Animals; Bone Development; Bone Resorption; Cell Membrane; Diphosphonates; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Organ Size; Osteoclasts; Ovariectomy; Pamidronate; Periosteum; Rats; Rats, Wistar; Tibia; Uterus | 1993 |
Regulation of avian osteoclastic H+ -ATPase and bone resorption by tamoxifen and calmodulin antagonists. Effects independent of steroid receptors.
Topics: Animals; Biological Transport; Bone Resorption; Calmodulin; Cell Membrane; Cells, Cultured; Chickens; Diethylstilbestrol; Drug Synergism; Estradiol; Female; Fulvestrant; Hydrochloric Acid; Osteoclasts; Proton-Translocating ATPases; Tamoxifen; Trifluoperazine | 1996 |